BR112019003957A2 - proteína de ligação a fator h modificado - Google Patents

proteína de ligação a fator h modificado

Info

Publication number
BR112019003957A2
BR112019003957A2 BR112019003957-0A BR112019003957A BR112019003957A2 BR 112019003957 A2 BR112019003957 A2 BR 112019003957A2 BR 112019003957 A BR112019003957 A BR 112019003957A BR 112019003957 A2 BR112019003957 A2 BR 112019003957A2
Authority
BR
Brazil
Prior art keywords
modified
binding protein
factor binding
fhbp
relates
Prior art date
Application number
BR112019003957-0A
Other languages
English (en)
Portuguese (pt)
Inventor
M Tang Christoph
Original Assignee
Oxford University Innovation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Limited filed Critical Oxford University Innovation Limited
Publication of BR112019003957A2 publication Critical patent/BR112019003957A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112019003957-0A 2016-08-31 2017-08-31 proteína de ligação a fator h modificado BR112019003957A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1614687.0 2016-08-31
GBGB1614687.0A GB201614687D0 (en) 2016-08-31 2016-08-31 fHbp scaffold
PCT/GB2017/052535 WO2018042178A1 (en) 2016-08-31 2017-08-31 Modified factor h binding protein

Publications (1)

Publication Number Publication Date
BR112019003957A2 true BR112019003957A2 (pt) 2019-06-25

Family

ID=57119942

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019003957-0A BR112019003957A2 (pt) 2016-08-31 2017-08-31 proteína de ligação a fator h modificado

Country Status (13)

Country Link
US (1) US12497432B2 (https=)
EP (1) EP3506934A1 (https=)
JP (1) JP7525093B2 (https=)
KR (1) KR102643280B1 (https=)
CN (1) CN109890412B (https=)
AU (1) AU2017319218B2 (https=)
BR (1) BR112019003957A2 (https=)
CA (1) CA3035159A1 (https=)
GB (2) GB201614687D0 (https=)
IL (1) IL265078B2 (https=)
MX (1) MX420767B (https=)
WO (1) WO2018042178A1 (https=)
ZA (1) ZA201901862B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
CN110903400A (zh) * 2019-11-08 2020-03-24 苏州微超生物科技有限公司 B群脑膜炎球菌fHBP多变体融合蛋白及其制备方法与应用
CN111533792B (zh) 2020-07-07 2020-10-16 康希诺生物股份公司 一种定点突变的载体蛋白及其在制备疫苗中的用途
WO2022071291A1 (ja) * 2020-09-29 2022-04-07 出光興産株式会社 ペプチドタグおよびそれを含むタグ付加タンパク質
IN202321021121A (https=) * 2023-03-24 2024-04-19

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
HUE031886T2 (en) * 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
AU2003300841B2 (en) * 2002-12-10 2008-03-20 Lorantis Ltd. Stabilized immunogenic HBc chimer particles
EP2172213B1 (en) * 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
NZ546430A (en) * 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
CA2574375C (en) * 2004-07-23 2015-03-17 Chiron Srl Polypeptides for oligomeric assembly of antigens
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
WO2006081259A2 (en) * 2005-01-27 2006-08-03 Children's Hospital & Research Center At Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
CN102356089B (zh) * 2008-02-21 2014-02-19 诺华股份有限公司 脑膜炎球菌fHBP多肽
AU2009223613B2 (en) * 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
UA99659C2 (uk) * 2008-05-30 2012-09-10 Дзе Ю.Ес.Ей., Ес Репрезентед Бай Дзе Секретарі Оф Дзе Армі, Он Бехаф Оф Уолтер Рід Армі Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
EP2294085A1 (en) * 2008-06-09 2011-03-16 Novartis AG Antibodies against neisserial factor h binding protein
EP2331562A4 (en) * 2008-09-03 2012-07-04 Childrens Hosp & Res Ct Oak PEPTIDES WITH AN EPITOPE OF A DOMAIN OF THE FACTOR H-BINDING PROTEIN AND METHOD OF USE
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
EP2411048B1 (en) * 2009-03-24 2020-05-06 GlaxoSmithKline Biologicals SA Adjuvanting meningococcal factor h binding protein
CA2759400A1 (en) * 2009-04-30 2010-11-04 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) and methods of use
CN102596240B (zh) * 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
CA2779816A1 (en) * 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
CA2792687A1 (en) * 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Immunogenic composition
TR201802933T4 (tr) * 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
WO2011125015A2 (en) * 2010-04-05 2011-10-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
AU2011268507B2 (en) * 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
AU2011300409B2 (en) * 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
JP2015505309A (ja) * 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
US10598666B2 (en) * 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) * 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) * 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
AU2013276083B2 (en) * 2012-06-14 2018-04-05 Institut Pasteur Vaccines for serogroup X meningococcus
GB201215005D0 (en) * 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
WO2014136064A2 (en) * 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
WO2014140562A1 (en) * 2013-03-14 2014-09-18 Isis Innovation Limited Immunogenic composition to neisseria
RU2662968C2 (ru) * 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
KR20160127104A (ko) * 2014-02-28 2016-11-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 변형된 수막구균 fhbp 폴리펩티드
KR102761870B1 (ko) * 2014-07-23 2025-02-05 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 인자 h 결합 단백질 변이체 및 이의 사용 방법
CA2967139A1 (en) * 2014-11-28 2016-06-02 Janssen Vaccines & Prevention B.V. Meningitis b vaccine
WO2016132294A1 (en) * 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
AU2018215585B2 (en) * 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Also Published As

Publication number Publication date
ZA201901862B (en) 2020-09-30
KR102643280B1 (ko) 2024-03-05
JP7525093B2 (ja) 2024-07-30
CN109890412B (zh) 2025-04-04
CN109890412A (zh) 2019-06-14
NZ751995A (en) 2024-03-22
MX2019002248A (es) 2019-09-18
MX420767B (es) 2025-02-10
AU2017319218B2 (en) 2021-10-28
GB2568440B (en) 2022-08-17
IL265078B2 (en) 2023-08-01
EP3506934A1 (en) 2019-07-10
GB2568440A (en) 2019-05-15
KR20190064577A (ko) 2019-06-10
JP2019526261A (ja) 2019-09-19
GB201614687D0 (en) 2016-10-12
US20220112249A1 (en) 2022-04-14
WO2018042178A1 (en) 2018-03-08
GB201903866D0 (en) 2019-05-08
AU2017319218A1 (en) 2019-04-18
US12497432B2 (en) 2025-12-16
CA3035159A1 (en) 2018-03-08
AU2017319218A2 (en) 2019-05-02
IL265078A (https=) 2019-04-30
IL265078B1 (en) 2023-04-01

Similar Documents

Publication Publication Date Title
BR112019003957A2 (pt) proteína de ligação a fator h modificado
PH12020550051A1 (en) Glp-1 compositions and uses thereof
BR112018073761A2 (pt) proteínas de ligação ao cd3 de fragmento variável de cadeia única
EA201892489A1 (ru) Число мишеней для мультиплексной оптимизированной амплификации с несоответствиями (moma)
BR112018076190A2 (pt) ortólogos e sistemas crispr tipo vi
AU2016240220B2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
MX383537B (es) Mutantes de proteína f de rsv.
EA201692309A1 (ru) Стереохимически обогащенные композиции для доставки нуклеиновых кислот
EP4477662A3 (en) Nucleic acid molecules and uses thereof
BR112018005928A2 (pt) composição ácida compreendendo uma ficocianina
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
BR112017001417A2 (pt) variantes de proteína de ligação ao fator h e métodos para uso das mesmas
MX385972B (es) Partículas y composiciones de nicotina.
WO2017053732A3 (en) Composition and method for treating complement-mediated disease
EP4218790A8 (en) Modulators of complement activity
MX2021004331A (es) Composiciones estables de semaglutida y usos de las mismas.
WO2018226992A8 (en) Tau aggregation inhibitors
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
EP4574207A3 (en) Means and methods for treating copper-related diseases
MX2017008567A (es) Dnasa modificada y usos de la misma.
MX2020008125A (es) Composiciones que comprenden berberina.
EP3972410C0 (fr) Composition pour la conservation des plaquettes sanguines
WO2016020880A3 (en) Angiopoietin-like 4 antibodies and methods of use
EP3789382A4 (en) PROCESS FOR THE PRODUCTION OF 4,5-DIHYDROISOXAZOLE 5,5-DISUBSTITUTED

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]